ImmuneOnco wins FDA IND clearance for IMM0306 lupus Phase Ib/II trial

• FDA cleared an IND for ImmuneOnco’s IMM0306, enabling a Phase Ib/II trial in systemic lupus erythematosus.
• IMM0306 is a CD47/CD20 bispecific antibody candidate.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Immuneonco Biopharmaceuticals (Shanghai) Co. Ltd. published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260821-12294776), on August 21, 2026, and is solely responsible for the information contained therein.